OGN Organon & Co. Earnings per share growth this year

Official company branding of Organon Pharma (OGN)

Year-over-year EPS growth demonstrates the dominance of Organon & Co. (OGN) in the women's health niche and high margins. The current status is -8.50. Organon & Co. is actively investing in biotechnological developments and reproductive medicine. A global network of plants and protected patents ensure the uninterrupted production of high-demand contraceptives.

Earnings per share growth in current year: Organon & Co (OGN) for 07/04/2022 - 11/12/2026

Financial and market metric breakdowns for Organon & Co. (OGN)

- stock value and consensus price forecast:
Market Price Organon & Co|OGN - Price Target Chart
- market capitalization data:
Market Capitalization Organon Pharma|OGN - Total Company Value
- book capitalization information:
Net Asset Value per Share Organon|OGN - Company Book Value|Market Value to Book Value organon.com|OGN - Company Total Assets
- debt and liquidity details:
Debt to Capital Ratio Organon & Co.|OGN - Long-Term Debt to Capital|Short-Term Debt to Capital organon.com|OGN - Company Debts|Debt to Book Value Ratio Organon Pharma|OGN - Company Long-Term Debt|Short-Term Debt Organon|Immediate Liquidity Ratio organon.com
- company profitability and valuation multiples indicators:
OGN - Net Income|Expected Net Income Organon & Co.|OGN - Price to Earnings Multiple|Market Cap to Future Earnings Ratio Organon Pharma|OGN - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Organon Pharma|OGN - Operating profit EBITDA|Net earnings per share for the last 12 months Organon|OGN - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months organon.com|OGN - Net earnings per share growth this year|Consensus forecast of earnings per share growth for next year Organon & Co.
Basic company analysis:Organon & Co
Original product of Organon & Co.

The integration of AI platforms and robotic assembly lines into Organon & Co. (OGN) production directly impacts annual net earnings per share dynamics by optimizing operating expenses. This indicator measures the percentage deviation of current EPS from the value of the same period last year, allowing investors to assess real capital resilience regardless of short-term market volatility and inflated expectations.

Main competitors

Earnings per share growth rate in current year Dare Bioscience (DARE)|Earnings per share growth in current year TherapeuticsMD Inc|Earnings per share growth this year PTN (Palatin Corp)